NCT07049848View on ClinicalTrials.gov

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Atezolizumab

Given by IV

DRUG

Doxorubicin Hydrochloride

Given by IV

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER